Kindeva’s Meridian Medical Technologies division has received a Defense Logistics Agency contract worth up to $226 million to supply nerve agent antidote autoinjectors for U.S. military use, the company announced Oct. 15.
The contract could cover more than 3 million Antidote Treatment Nerve Agent Autoinjectors, known as ATNAA. Kindeva will manufacture the devices at its St. Louis, Missouri, campus and supply them through its autoinjector assembly operations.
ATNAA delivers atropine and pralidoxime chloride to treat poisoning caused by organophosphorus nerve agents and organophosphorus insecticides. The dual-chamber device is intended to support military personnel facing potential chemical exposure.
The Defense Logistics Agency procures and distributes equipment, medical products and other resources for the Army, Navy, Air Force, Marine Corps and additional federal agencies. The agreement covers manufacture and delivery of ATNAA for agency customers.
Kindeva also manufactures DuoDote, a civilian version supplied to other U.S. government agencies, first responders and more than 30 allied nations for preparedness against mass casualty events.
According to the company, ATNAA and DuoDote are the only FDA-approved dual-chamber autoinjectors for nerve agent antidotes that administer both atropine and pralidoxime chloride.
Tara Butler, Kindeva’s director of government contracts for global health security, said the award followed more than a year of work with the agency. She described Kindeva as the sole supplier of the countermeasure.